<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2023-10-2-146-153</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-849</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭНДОКРИНОЛОГИЧЕСКИЕ ЗАБОЛЕВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>METABOLIC DISEASES</subject></subj-group></article-categories><title-group><article-title>НЕАЛКОГОЛЬНАЯ ЖИРОВАЯ БОЛЕЗНЬ ПЕЧЕНИ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА: ВОЗМОЖНОСТИ МЕТОДОВ ЛУЧЕВОЙ ДИАГНОСТИКИ</article-title><trans-title-group xml:lang="en"><trans-title>NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: MODERN IMAGING MODALITIES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабенко</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Babenko</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабенко Алина Юрьевна, д.м.н., профессор кафедры эндокринологии, Институт медицинского образования, заведующий НИО генетических рисков и персонифицированной профилактики, НЦМУ «Центр персонализированной медицины», главный научный сотрудник научно-исследовательской лаборатории диабетологии, Институт эндокринологии, врач-эндокринолог высшей категории</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Alina Yu. Babenko, D. M. Sc., Professor, Department of Endocrinology, Institute of Medical Education, Almazov National Medical Research Centre; Head of Research Institute of Genetic Risks and Personalized Prevention, World-Class Research Center for Personalised medicine; Head, Leading Research Scientist, Diabetology Research Laboratory, Institute of Endocrinology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лаевская</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Laevskaya</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаевская Мария Юрьевна, к.м.н., доцент кафедры эндокринологии, Институт медицинского образования, старший научный сотрудник научно-исследовательской лаборатории диабетологии, Институт эндокринологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Maria Yu. Laevskaya, MD, Associate Professor, Department of Endocrinology, Institute of Medical Education, Senior Research Scientist, Research Laboratory of Diabetology, Institute of Endocrinology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мелтонян</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Meltonian</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мелтонян Ася Робертовна, аспирант кафедры эндокринологии, врач-эндокринолог</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, 197341</p></bio><bio xml:lang="en"><p>Asia R. Meltonian, MD, Postgraduate Student, Endocrinologist, Department of Endocrinology, Institute of Medical Education</p><p>Akkuratova str., 2, Saint Petersburg, 197341</p></bio><email xlink:type="simple">meltonyan_ar@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченков</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenkov</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савченков Юрий Николаевич, к.м.н., ассистент кафедры лучевой диагностики с курсом радиологии, Медико-биологический университет инноваций и непрерывного образования</p><p>Москва</p></bio><bio xml:lang="en"><p>Yurii N. Savchenkov, MD, Assistant, Department of Radiology</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Труфанов</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Trufanov</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Труфанов Геннадий Евгеньевич, д.м.н., профессор, заведующий научно-исследовательским отделом лучевой диагностики</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Gennady Ye. Trufanov, D.M.Sc., Professor, Head, Department of Radiology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Государственный научный центр Российской Федерации - Федеральный медицинский биофизический центр имени А. И. Бурназяна» Федерального медико-биологического агентства России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Burnasyan Federal Medical Research Biophysical Center of Federal Medical Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>25</day><month>08</month><year>2023</year></pub-date><volume>10</volume><issue>3</issue><fpage>146</fpage><lpage>153</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бабенко А.Ю., Лаевская М.Ю., Мелтонян А.Р., Савченков Ю.Н., Труфанов Г.Е., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Бабенко А.Ю., Лаевская М.Ю., Мелтонян А.Р., Савченков Ю.Н., Труфанов Г.Е.</copyright-holder><copyright-holder xml:lang="en">Babenko A.Y., Laevskaya M.Y., Meltonian A.R., Savchenkov Y.N., Trufanov G.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/849">https://transmed.almazovcentre.ru/jour/article/view/849</self-uri><abstract><p>Неалкогольная жировая болезнь (НАЖБП) — это наиболее распространенное заболевание печени и одно из наиболее частых показаний к ее трансплантации в развитых странах мира. Сахарный диабет 2 типа (СД 2) является важным фактором риска развития НАЖБП. СД 2, согласно имеющимся данным, ускоряет прогрессирование НАЖБП, поэтому в этой группе больных возможности диагностической визуализации печени приобретают большее значение, чем у пациентов с НАЖБП в отсутствие СД 2. Кроме того, в клинической практике данное заболевание остается недиагностированным более чем в половине случаев, а его течение — трудно прогнозируемым.Следует отметить, что золотым стандартом диагностики НАЖБП по-прежнему является биопсия печени, однако метод имеет ряд очевидных недостатков ввиду инвазивности, невозможности его частого выполнения в рутинной практике, неприменимости для оценки динамики НАЖБП в ходе лечения, а также относительно высокой стоимости. В связи с этим ведется поиск новых неинвазивных методов диагностики НАЖБП, особенно на ранних стадиях.Лучевая диагностика НАЖБП основывается на использовании ультразвукового исследования (УЗИ), компьютерной томографии (КТ) и магнитно-резонансной томографии (МРТ), чувствительность и специфичность которых значительно варьируют. Таким образом, в данном обзоре обсуждаются современные методики неинвазивной инструментальной диагностики различных видов НАЖБП у пациентов с СД 2, которые потенциально могут иметь важное прогностическое значение.</p></abstract><trans-abstract xml:lang="en"><p>Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and one of the most common cause of liver transplantation in developed countries. Type 2 diabetes mellitus (T2DM) is an important risk factor for NAFLD. Additionally, T2DM is believed to accelerate the progression of NAFLD. Therefore, the use of different imaging modalities in this patient cohort appears to be more important than in patients with NAFLD without diabetes mellitus. Moreover, NAFLD is often overlooked in clinical practice. It should be noted that the gold standard for diagnosing NAFLD is still a liver biopsy, however, the method has a number of obvious disadvantages in terms of invasiveness, the impossibility of its frequent use in routine practice, its inapplicability for assessing the dynamics of NAFLD during treatment, and relatively high cost. In this regard, work is underway to find new non-invasive methods for diagnosing NAFLD, especially in the early stages. Radiation diagnosis of NAFLD is based on the use of ultrasound (ultrasound), computed tomography (CT) and magnetic resonance imaging (MRI), the sensitivity and specificity of which vary considerably. Thus, this review summarizes and discusses modern methods of non-invasive diagnosis of different types of NAFLD in patients with T2DM that can potentially have an important prognostic value.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>магнитно-резонансная томография</kwd><kwd>неалкогольная жировая болезнь печени</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>стеатоз</kwd><kwd>ультразвуковое исследование</kwd><kwd>фиброз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diagnostic imaging</kwd><kwd>fibrosis</kwd><kwd>magnetic resonance imaging</kwd><kwd>non-alcoholic fatty liver disease</kwd><kwd>steatosis</kwd><kwd>type 2 diabetes</kwd><kwd>ultrasound</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при поддержке следующего источника: государственное задание № 44, регистрационный номер 122041900080-5.</funding-statement><funding-statement xml:lang="en">The study was carried out with the support of the following source: State assignment No. 44, registration number 122041900080-5.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119. DOI: 10.1016/j.diabres.2021.109119.</mixed-citation><mixed-citation xml:lang="en">Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119. DOI: 10.1016/j.diabres.2021.109119.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan S, Chen J, Li X, et al. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study. Eur J Epidemiol. 2022; 37(7):723–733. DOI: 10.1007/s10654-022-00868-3</mixed-citation><mixed-citation xml:lang="en">Yuan S, Chen J, Li X, et al. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study. Eur J Epidemiol. 2022; 37(7):723–733. DOI: 10.1007/s10654-022-00868-3</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851–861. DOI: 10.1016/S2468-1253(22)00165-0</mixed-citation><mixed-citation xml:lang="en">Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851–861. DOI: 10.1016/S2468-1253(22)00165-0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi ZM. Non-alcoholic fatty liver disease — A global public health perspective. J Hepatol. 2019; 70(3):531–544. DOI: 10.1016/j.jhep.2018.10.033.</mixed-citation><mixed-citation xml:lang="en">Younossi ZM. Non-alcoholic fatty liver disease — A global public health perspective. J Hepatol. 2019; 70(3):531–544. DOI: 10.1016/j.jhep.2018.10.033.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018; 48(7):696–703. DOI: 10.1111/apt.14937.</mixed-citation><mixed-citation xml:lang="en">Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018; 48(7):696–703. DOI: 10.1111/apt.14937.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18(9):599–612. DOI: 10.1038/s41575-021-00448-y.</mixed-citation><mixed-citation xml:lang="en">Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18(9):599–612. DOI: 10.1038/s41575-021-00448-y.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shetty AS, Sipe AL, Zulfiqar M, et al. In-Phase and Opposed-Phase Imaging: Applications of Chemical Shift and Magnetic Susceptibility in the Chest and Abdomen. Radiographics. 2019; 39(1):115–135. DOI: 10.1148/rg.2019180043.</mixed-citation><mixed-citation xml:lang="en">Shetty AS, Sipe AL, Zulfiqar M, et al. In-Phase and Opposed-Phase Imaging: Applications of Chemical Shift and Magnetic Susceptibility in the Chest and Abdomen. Radiographics. 2019; 39(1):115–135. DOI: 10.1148/rg.2019180043.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Seifeldein GS, Hassan EA, Imam HM, et al. Quantitative MDCT and MRI assessment of hepatic steatosis in genotype 4 chronic hepatitis C patients with fibrosis Egypt J Radiol Nucl Med. 2021; 52:210. DOI: 10.1186/s43055-021-00590-2.</mixed-citation><mixed-citation xml:lang="en">Seifeldein GS, Hassan EA, Imam HM, et al. Quantitative MDCT and MRI assessment of hepatic steatosis in genotype 4 chronic hepatitis C patients with fibrosis Egypt J Radiol Nucl Med. 2021; 52:210. DOI: 10.1186/s43055-021-00590-2.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Диомидова В.Н., Тарасова Л.В., Цыганова Ю.В. и др. Ультразвуковая эластография печени с технологией затухающего сигнала позволяет оценить степень стеатоза и осуществлять динамическое наблюдение эффективности лечения НАЖБП. Экспе- риментальная и клиническая гастроэнтерология. 2020; (9):45–54. DOI: 10.31146/1682-8658-ecg-181-9-45-54.</mixed-citation><mixed-citation xml:lang="en">Diomidova VN, Tarasova LV, Tsyganova YuV, et al. Ultrasound hepatic elastography with decaying signal technology allows assessing the degree of steatosis and dynamic monitoring of the effectiveness of NAFLD treatment. Experimental and Clinical Gastroenterology. 2020; (9):45–54.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraioli G, Soares Monteiro LB. Ultrasoundbased techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019; 25(40):6053–6062. DOI: 10.3748/wjg.v25.i40.6053.</mixed-citation><mixed-citation xml:lang="en">Ferraioli G, Soares Monteiro LB. Ultrasoundbased techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019; 25(40):6053–6062. DOI: 10.3748/wjg.v25.i40.6053.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraioli G, Berzigotti A, Barr RG, et al. Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound Med Biol. 2021; 47(10):2803–2820. DOI: 10.1016/j.ultrasmedbio.2021.06.002.</mixed-citation><mixed-citation xml:lang="en">Ferraioli G, Berzigotti A, Barr RG, et al. Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound Med Biol. 2021; 47(10):2803–2820. DOI: 10.1016/j.ultrasmedbio.2021.06.002.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54(3):1082–1090. DOI: 10.1002/hep.24452.</mixed-citation><mixed-citation xml:lang="en">Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54(3):1082–1090. DOI: 10.1002/hep.24452.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006; 38(7):485–489. DOI: 10.1016/j.dld.2006.03.021.</mixed-citation><mixed-citation xml:lang="en">Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006; 38(7):485–489. DOI: 10.1016/j.dld.2006.03.021.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chan WK, Nik Mustapha NR, Mahadeva S, et al. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? J Gastroenterol Hepatol. 2018; 33(10):1787–1794. DOI: 10.1111/jgh.14150.</mixed-citation><mixed-citation xml:lang="en">Chan WK, Nik Mustapha NR, Mahadeva S, et al. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? J Gastroenterol Hepatol. 2018; 33(10):1787–1794. DOI: 10.1111/jgh.14150.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51(6):1061–1067. DOI: 10.1016/j.jhep.2009.09.001.</mixed-citation><mixed-citation xml:lang="en">Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51(6):1061–1067. DOI: 10.1016/j.jhep.2009.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol. 2017; 23(4):290–301. DOI: 10.3350/cmh.2017.0042.</mixed-citation><mixed-citation xml:lang="en">Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol. 2017; 23(4):290–301. DOI: 10.3350/cmh.2017.0042.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hepburn MJ, Vos JA, Fillman EP, et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol. 2005; 5:14. DOI: 10.1186/1471-230X-5-14.</mixed-citation><mixed-citation xml:lang="en">Hepburn MJ, Vos JA, Fillman EP, et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol. 2005; 5:14. DOI: 10.1186/1471-230X-5-14.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021; 75(4):770–785. DOI: 10.1016/j.jhep.2021.04.044.</mixed-citation><mixed-citation xml:lang="en">Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021; 75(4):770–785. DOI: 10.1016/j.jhep.2021.04.044.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19(1):51. DOI: 10.1186/s12876-019-0961-9.</mixed-citation><mixed-citation xml:lang="en">Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19(1):51. DOI: 10.1186/s12876-019-0961-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66(5):1022–1030. DOI: 10.1016/j.jhep.2016.12.022.</mixed-citation><mixed-citation xml:lang="en">Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66(5):1022–1030. DOI: 10.1016/j.jhep.2016.12.022.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu C, Caussy C, Imajo K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019; 17(4):630–637.e8. DOI: 10.1016/j.cgh.2018.05.059.</mixed-citation><mixed-citation xml:lang="en">Hsu C, Caussy C, Imajo K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019; 17(4):630–637.e8. DOI: 10.1016/j.cgh.2018.05.059.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017; 66(5):1486–1501. DOI: 10.1002/hep.29302.</mixed-citation><mixed-citation xml:lang="en">Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017; 66(5):1486–1501. DOI: 10.1002/hep.29302.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology. 2019; 70(5):1521–1530. DOI: 10.1002/hep.30842.</mixed-citation><mixed-citation xml:lang="en">Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology. 2019; 70(5):1521–1530. DOI: 10.1002/hep.30842.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019; 71(2):389–396. DOI: 10.1016/j.jhep.2019.04.020.</mixed-citation><mixed-citation xml:lang="en">Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019; 71(2):389–396. DOI: 10.1016/j.jhep.2019.04.020.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Van Dijk AM, Vali Y, Mak AL, et al. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med. 2021; 10(13):2910. DOI: 10.3390/jcm10132910.</mixed-citation><mixed-citation xml:lang="en">Van Dijk AM, Vali Y, Mak AL, et al. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med. 2021; 10(13):2910. DOI: 10.3390/jcm10132910.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Loong TC, Wei JL, Leung JC, et al. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2017; 32(7):1363–1369. DOI: 10.1111/jgh.13671.</mixed-citation><mixed-citation xml:lang="en">Loong TC, Wei JL, Leung JC, et al. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2017; 32(7):1363–1369. DOI: 10.1111/jgh.13671.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall Med. 2017; 38(4):377–394. DOI: 10.1055/s-0043-103955.</mixed-citation><mixed-citation xml:lang="en">Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall Med. 2017; 38(4):377–394. DOI: 10.1055/s-0043-103955.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020; 9(4):1005. DOI: 10.3390/cells9041005.</mixed-citation><mixed-citation xml:lang="en">Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020; 9(4):1005. DOI: 10.3390/cells9041005.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraioli G, Tinelli C, Lissandrin R, et al. Ultrasound point shear wave elastography assessment of liver and spleen stiffness: effect of training on repeatability of measurements. Eur Radiol. 2014; 24(6):1283–1289. DOI: 10.1007/s00330-014-3140-y.</mixed-citation><mixed-citation xml:lang="en">Ferraioli G, Tinelli C, Lissandrin R, et al. Ultrasound point shear wave elastography assessment of liver and spleen stiffness: effect of training on repeatability of measurements. Eur Radiol. 2014; 24(6):1283–1289. DOI: 10.1007/s00330-014-3140-y.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med. 2017; 38(4):e16–e47. DOI: 10.1055/s-0043-103952.</mixed-citation><mixed-citation xml:lang="en">Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med. 2017; 38(4):e16–e47. DOI: 10.1055/s-0043-103952.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Jamialahmadi T, Nematy M, Jangjoo A, et al. Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy. Obes Surg. 2019; 29(8):2585–2592. DOI: 10.1007/s11695-019-03889-2.</mixed-citation><mixed-citation xml:lang="en">Jamialahmadi T, Nematy M, Jangjoo A, et al. Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy. Obes Surg. 2019; 29(8):2585–2592. DOI: 10.1007/s11695-019-03889-2.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Rajamani AS, Rammohan A, Sai VVR, et al. Current techniques and future trends in the diagnosis of hepatic steatosis in liver donors: A review Journal of Liver Transplantation. 2022; 7:100091. DOI: 10.1016/j.liver.2022.100091.</mixed-citation><mixed-citation xml:lang="en">Rajamani AS, Rammohan A, Sai VVR, et al. Current techniques and future trends in the diagnosis of hepatic steatosis in liver donors: A review Journal of Liver Transplantation. 2022; 7:100091. DOI: 10.1016/j.liver.2022.100091.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rastogi R, Gupta S, Garg B, et al. Comparative accuracy of CT, dual-echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors. Indian J Radiol Imaging. 2016; 26(1):5–14. DOI: 10.4103/0971-3026.178281.</mixed-citation><mixed-citation xml:lang="en">Rastogi R, Gupta S, Garg B, et al. Comparative accuracy of CT, dual-echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors. Indian J Radiol Imaging. 2016; 26(1):5–14. DOI: 10.4103/0971-3026.178281.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Wang C, Duanmu Y, et al. Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic steatosis. Br J Radiol. 2018; 91(1091):20170587. DOI: 10.1259/bjr.20170587.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Wang C, Duanmu Y, et al. Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic steatosis. Br J Radiol. 2018; 91(1091):20170587. DOI: 10.1259/bjr.20170587.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang PP, Choi HH, Ohliger MA. Detection of fatty liver using virtual non-contrast dual-energy CT. Abdom Radiol (NY). 2022; 47(6):2046–2056. DOI: 10.1007/s00261-022-03482-9.</mixed-citation><mixed-citation xml:lang="en">Zhang PP, Choi HH, Ohliger MA. Detection of fatty liver using virtual non-contrast dual-energy CT. Abdom Radiol (NY). 2022; 47(6):2046–2056. DOI: 10.1007/s00261-022-03482-9.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang YN, Fowler KJ, Hamilton G, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018; 91(1089):20170959. DOI: 10.1259/bjr.20170959.</mixed-citation><mixed-citation xml:lang="en">Zhang YN, Fowler KJ, Hamilton G, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018; 91(1089):20170959. DOI: 10.1259/bjr.20170959.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Lamb P, Sahani DV, Fuentes-Orrego JM, et al. Stratification of patients with liver fibrosis using dualenergy CT. IEEE Trans Med Imaging. 2015; 34(3):807–815. DOI: 10.1109/TMI.2014.2353044.</mixed-citation><mixed-citation xml:lang="en">Lamb P, Sahani DV, Fuentes-Orrego JM, et al. Stratification of patients with liver fibrosis using dualenergy CT. IEEE Trans Med Imaging. 2015; 34(3):807–815. DOI: 10.1109/TMI.2014.2353044.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Аллахвердиева Я.С., Воробьев С.В., Минеев Н.И. Современные возможности магнитно-резонансных технологий в диагностике ожирения печени. Медицинский вестник Северного Кавказа. 2018; 13(4):695–700. DOI: 10.14300/mnnc.2018.13140.</mixed-citation><mixed-citation xml:lang="en">Allakhverdieva YaS, Vorob’ev SV, Mineev NI. Modern opportunities of magnetic-resonance technologies in diagnostics of the fatty liver. Medical news of the North Caucasus. 2018; 13(4): 695–700.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019; 70(1):133–141. DOI: 10.1016/j.jhep.2018.09.024.</mixed-citation><mixed-citation xml:lang="en">Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019; 70(1):133–141. DOI: 10.1016/j.jhep.2018.09.024.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Caussy C, Reeder SB, Sirlin CB, et al. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology. 2018; 68(2):763–772. DOI: 10.1002/hep.29797.</mixed-citation><mixed-citation xml:lang="en">Caussy C, Reeder SB, Sirlin CB, et al. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology. 2018; 68(2):763–772. DOI: 10.1002/hep.29797.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gu J, Liu S, Du S, et al. Diagnostic value of MRIPDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019; 29(7):3564–3573. DOI: 10.1007/s00330-019-06072-4.</mixed-citation><mixed-citation xml:lang="en">Gu J, Liu S, Du S, et al. Diagnostic value of MRIPDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019; 29(7):3564–3573. DOI: 10.1007/s00330-019-06072-4.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013; 267(2):422–431. DOI: 10.1148/radiol.12120896.</mixed-citation><mixed-citation xml:lang="en">Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013; 267(2):422–431. DOI: 10.1148/radiol.12120896.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bonekamp S, Tang A, Mashhood A, et al. Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2014; 39(6):1525–1532. DOI: 10.1002/jmri.24321.</mixed-citation><mixed-citation xml:lang="en">Bonekamp S, Tang A, Mashhood A, et al. Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2014; 39(6):1525–1532. DOI: 10.1002/jmri.24321.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Yoneda M, Honda Y, Ogawa Y, et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021; 9(1):e001990. DOI: 10.1136/bmjdrc-2020-001990.</mixed-citation><mixed-citation xml:lang="en">Yoneda M, Honda Y, Ogawa Y, et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021; 9(1):e001990. DOI: 10.1136/bmjdrc-2020-001990.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016; 43(1):83–95. DOI: 10.1111/apt.13405.</mixed-citation><mixed-citation xml:lang="en">Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016; 43(1):83–95. DOI: 10.1111/apt.13405.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Simchick G, Zhao R, Hamilton G, et al. Spectroscopy-based multi-parametric quantification in subjects with liver iron overload at 1.5T and 3T. Magn Reson Med. 2022; 87(2):597–613. DOI: 10.1002/mrm.29021.</mixed-citation><mixed-citation xml:lang="en">Simchick G, Zhao R, Hamilton G, et al. Spectroscopy-based multi-parametric quantification in subjects with liver iron overload at 1.5T and 3T. Magn Reson Med. 2022; 87(2):597–613. DOI: 10.1002/mrm.29021.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Шария М.А., Ширяев Г.А., Устюжанин Д.В. Протонная магнитно-резонансная спектроскопия в диагностическом алгоритме у пациента с неалкогольной жировой болезнью печени при комплексном подходе к лечению. REJR. 2014; 4(3): 91–93.</mixed-citation><mixed-citation xml:lang="en">Sharia MA, Shiryaev GA, Ustyuzhanin DV. Proton Magnetic Resonance Spectroscopy in a Diagnostic Algorithm in a Patient with Non-alcoholic Fat Liver Disease in an Integrated Approach to Treatment. REJR. 2014; 4(3):91–93.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Yokoo T, Serai SD, Pirasteh A, et al. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology. 2018; 286(2):486–498. DOI: 10.1148/radiol.2017170550.</mixed-citation><mixed-citation xml:lang="en">Yokoo T, Serai SD, Pirasteh A, et al. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology. 2018; 286(2):486–498. DOI: 10.1148/radiol.2017170550.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Roumans KHM, Lindeboom L, Veeraiah P, et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat. Commun. 2020; 11:1891. DOI: 10.1038/s41467-020-15684-0.</mixed-citation><mixed-citation xml:lang="en">Roumans KHM, Lindeboom L, Veeraiah P, et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat. Commun. 2020; 11:1891. DOI: 10.1038/s41467-020-15684-0.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Trout AT, Serai S, Mahley AD, et al. Liver Stiffness Measurements with MR Elastography: Agreement and Repeatability across Imaging Systems, Field Strengths, and Pulse Sequences. Radiology. 2016; 281(3):793–804. DOI: 10.1148/radiol.2016160209.</mixed-citation><mixed-citation xml:lang="en">Trout AT, Serai S, Mahley AD, et al. Liver Stiffness Measurements with MR Elastography: Agreement and Repeatability across Imaging Systems, Field Strengths, and Pulse Sequences. Radiology. 2016; 281(3):793–804. DOI: 10.1148/radiol.2016160209.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Serai SD, Obuchowski NA, Venkatesh SK, et al. Repeatability of MR Elastography of Liver: A Meta-Analysis. Radiology. 2017; 285(1):92–100. DOI: 10.1148/radiol.2017161398.</mixed-citation><mixed-citation xml:lang="en">Serai SD, Obuchowski NA, Venkatesh SK, et al. Repeatability of MR Elastography of Liver: A Meta-Analysis. Radiology. 2017; 285(1):92–100. DOI: 10.1148/radiol.2017161398.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol. 2014; 20(31):10851–10863. DOI: 10.3748/wjg.v20.i31.10851.</mixed-citation><mixed-citation xml:lang="en">Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol. 2014; 20(31):10851–10863. DOI: 10.3748/wjg.v20.i31.10851.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Kim BH, Lee JM, Lee YJ, et al. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. J Magn Reson Imaging. 2011; 34(5):1110–1116. DOI: 10.1002/jmri.22723.</mixed-citation><mixed-citation xml:lang="en">Kim BH, Lee JM, Lee YJ, et al. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. J Magn Reson Imaging. 2011; 34(5):1110–1116. DOI: 10.1002/jmri.22723.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(23):7392–7402. DOI: 10.3748/wjg.v20.i23.7392.</mixed-citation><mixed-citation xml:lang="en">Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(23):7392–7402. DOI: 10.3748/wjg.v20.i23.7392.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Imajo K, Kessoku T, Honda Y, et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2016; 150(3):626–637.e7. DOI: 10.1053/j.gastro.2015.11.048.</mixed-citation><mixed-citation xml:lang="en">Imajo K, Kessoku T, Honda Y, et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2016; 150(3):626–637.e7. DOI: 10.1053/j.gastro.2015.11.048.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
